Mannkind (MNKD) Cost of Revenue (2015 - 2026)
Mannkind (MNKD) reported Cost of Revenue of $7.5 million for Q1 2026, up 99.28% year-over-year from $3.8 million in Q1 2025, and down 46.08% quarter-over-quarter from $13.9 million in Q4 2025.
Mannkind (MNKD) Cost of Revenue (2015 - 2026) Analysis & Trends
Mannkind (MNKD) has 12 years of Cost of Revenue data on file, last reported at $7.5 million in Q1 2026.
- Cost of Revenue for Q1 2026 came in at $7.5 million, up 99.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.5 million (up 75.75% YoY), and the FY2025 annual result was $26.8 million, up 53.77% from the prior year.
- Cost of Revenue declined to $7.5 million in Q1 2026 per MNKD's latest filing, from $13.9 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $14.0 million in Q2 2023 and troughed at -$26.1 million in Q4 2022.
- A 5-year average of $4.6 million and a median of $4.8 million in 2024 frame the typical range for Cost of Revenue.
- On a YoY basis, Cost of Revenue climbed as much as 255.22% in 2022 and fell as far as 179.22% in 2022.
- A 5-year view of Cost of Revenue shows it stood at -$26.1 million in 2022, then advanced by 23.9% to -$19.9 million in 2023, then surged by 124.17% to $4.8 million in 2024, then jumped by 189.66% to $13.9 million in 2025, then slumped by 46.08% to $7.5 million in 2026.
- Business Quant data shows MNKD's Cost of Revenue at $7.5 million in Q1 2026, $13.9 million in Q4 2025, and $4.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 64.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 48,670.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 392.80 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 2.05 Mn |
| 10 | Mannkind | 1.13 Bn | 995.19 Mn | 82.66 Mn | 7.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.51 Mn |
| Mar 31, 2026 | 7.51 Mn |
| Dec 31, 2025 | 13.93 Mn |
| Dec 31, 2025 | 13.93 Mn |
| Sep 30, 2025 | 4.50 Mn |
| Sep 30, 2025 | 4.50 Mn |
| Jun 30, 2025 | 4.61 Mn |
| Jun 30, 2025 | 4.61 Mn |
| Mar 31, 2025 | 3.77 Mn |
| Mar 31, 2025 | 3.77 Mn |
| Dec 31, 2024 | 4.81 Mn |
| Dec 31, 2024 | 4.81 Mn |
| Sep 30, 2024 | 3.20 Mn |
| Sep 30, 2024 | 3.20 Mn |
| Jun 30, 2024 | 5.61 Mn |
| Jun 30, 2024 | 5.61 Mn |
| Mar 31, 2024 | 3.82 Mn |
| Mar 31, 2024 | 3.82 Mn |
| Dec 31, 2023 | -19.89 Mn |
| Dec 31, 2023 | -19.89 Mn |